S&P 500   5,138.29 (+0.02%)
DOW   39,061.92 (-0.07%)
QQQ   445.01 (-0.13%)
AAPL   174.20 (-3.04%)
MSFT   416.19 (+0.17%)
META   502.63 (+0.07%)
GOOGL   132.82 (-3.15%)
AMZN   178.43 (+0.12%)
TSLA   188.00 (-7.22%)
NVDA   860.75 (+4.61%)
NIO   5.35 (-7.44%)
AMD   206.69 (+2.00%)
BABA   71.98 (-3.54%)
T   16.86 (-0.71%)
F   12.85 (+3.21%)
MU   96.66 (+1.59%)
CGC   3.00 (-6.54%)
GE   160.75 (+1.32%)
DIS   113.12 (+1.05%)
AMC   4.26 (-2.29%)
PFE   25.96 (-2.37%)
PYPL   59.52 (-1.68%)
XOM   104.30 (-1.46%)
S&P 500   5,138.29 (+0.02%)
DOW   39,061.92 (-0.07%)
QQQ   445.01 (-0.13%)
AAPL   174.20 (-3.04%)
MSFT   416.19 (+0.17%)
META   502.63 (+0.07%)
GOOGL   132.82 (-3.15%)
AMZN   178.43 (+0.12%)
TSLA   188.00 (-7.22%)
NVDA   860.75 (+4.61%)
NIO   5.35 (-7.44%)
AMD   206.69 (+2.00%)
BABA   71.98 (-3.54%)
T   16.86 (-0.71%)
F   12.85 (+3.21%)
MU   96.66 (+1.59%)
CGC   3.00 (-6.54%)
GE   160.75 (+1.32%)
DIS   113.12 (+1.05%)
AMC   4.26 (-2.29%)
PFE   25.96 (-2.37%)
PYPL   59.52 (-1.68%)
XOM   104.30 (-1.46%)
S&P 500   5,138.29 (+0.02%)
DOW   39,061.92 (-0.07%)
QQQ   445.01 (-0.13%)
AAPL   174.20 (-3.04%)
MSFT   416.19 (+0.17%)
META   502.63 (+0.07%)
GOOGL   132.82 (-3.15%)
AMZN   178.43 (+0.12%)
TSLA   188.00 (-7.22%)
NVDA   860.75 (+4.61%)
NIO   5.35 (-7.44%)
AMD   206.69 (+2.00%)
BABA   71.98 (-3.54%)
T   16.86 (-0.71%)
F   12.85 (+3.21%)
MU   96.66 (+1.59%)
CGC   3.00 (-6.54%)
GE   160.75 (+1.32%)
DIS   113.12 (+1.05%)
AMC   4.26 (-2.29%)
PFE   25.96 (-2.37%)
PYPL   59.52 (-1.68%)
XOM   104.30 (-1.46%)
S&P 500   5,138.29 (+0.02%)
DOW   39,061.92 (-0.07%)
QQQ   445.01 (-0.13%)
AAPL   174.20 (-3.04%)
MSFT   416.19 (+0.17%)
META   502.63 (+0.07%)
GOOGL   132.82 (-3.15%)
AMZN   178.43 (+0.12%)
TSLA   188.00 (-7.22%)
NVDA   860.75 (+4.61%)
NIO   5.35 (-7.44%)
AMD   206.69 (+2.00%)
BABA   71.98 (-3.54%)
T   16.86 (-0.71%)
F   12.85 (+3.21%)
MU   96.66 (+1.59%)
CGC   3.00 (-6.54%)
GE   160.75 (+1.32%)
DIS   113.12 (+1.05%)
AMC   4.26 (-2.29%)
PFE   25.96 (-2.37%)
PYPL   59.52 (-1.68%)
XOM   104.30 (-1.46%)
NASDAQ:OSUR

OraSure Technologies (OSUR) Stock Price, News & Analysis

$6.96
-0.31 (-4.26%)
(As of 12:45 PM ET)
Today's Range
$6.91
$7.30
50-Day Range
$6.71
$8.35
52-Week Range
$4.38
$8.45
Volume
559,363 shs
Average Volume
782,691 shs
Market Capitalization
$511.42 million
P/E Ratio
9.67
Dividend Yield
N/A
Price Target
$6.33

OraSure Technologies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
9.3% Downside
$6.33 Price Target
Short Interest
Bearish
5.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.09
Upright™ Environmental Score
News Sentiment
0.74mentions of OraSure Technologies in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$194,238 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.06) to $0.01 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.19 out of 5 stars

Medical Sector

384th out of 948 stocks

Surgical & Medical Instruments Industry

45th out of 96 stocks


OSUR stock logo

About OraSure Technologies Stock (NASDAQ:OSUR)

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's diagnostic products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgeneGUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

OSUR Stock Price History

OSUR Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Q4 2023 OraSure Technologies Inc Earnings Call
OraSure Technologies: Q4 Earnings Insights
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
OraSure Reports Q4 ‘23 Revenue of $75.9 Million
Preview: OraSure Technologies's Earnings
OSUR Mar 2024 10.000 put
Orasure Technologies Inc.
3 Strong Buy Stocks Under $10: January 2024
OraSure Technologies Inc OSUR
KLAC and ALKS are among after hour movers
OraSure to Participate in Upcoming Investor Conferences
Q3 2023 OraSure Technologies Inc Earnings Call
See More Headlines
Receive OSUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OraSure Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/04/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:OSUR
CUSIP
68554V10
Employees
840
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.33
High Stock Price Target
$9.00
Low Stock Price Target
$5.00
Potential Upside/Downside
-12.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-17,930,000.00
Pretax Margin
13.88%

Debt

Sales & Book Value

Annual Sales
$452.67 million
Cash Flow
$1.34 per share
Book Value
$5.86 per share

Miscellaneous

Free Float
70,692,000
Market Cap
$534.23 million
Optionable
Optionable
Beta
0.17

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Ms. Carrie Eglinton Manner (Age 49)
    President, CEO & Director
    Comp: $1.42M
  • Mr. Kenneth J. McGrath (Age 52)
    Chief Financial Officer
    Comp: $701.58k
  • Ms. Kathleen Gallagher Weber (Age 57)
    Chief Product Officer
    Comp: $890.87k
  • Ms. Michele Anthony (Age 49)
    Senior VP, Chief Accounting Officer, Controller & Assistant Secretary
  • Mr. Rafal Iwasiow Ph.D.
    Vice President of Science, Innovation & Technology
  • Mr. Jason Michael Plagman
    Vice President of Investor Relations
  • Mr. Stefano Taucer
    General Counsel & Corporate Secretary
  • Mr. David A. Rappaport C.F.A.
    Senior Vice President Corporate Development, Strategy & Integration
  • Amy Steigerwalt
    Senior Vice President of Human Resources
  • Mr. Zachary Wert
    Senior Vice President of Global Operations














OSUR Stock Analysis - Frequently Asked Questions

Should I buy or sell OraSure Technologies stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OSUR shares.
View OSUR analyst ratings
or view top-rated stocks.

What is OraSure Technologies' stock price target for 2024?

2 Wall Street research analysts have issued 12 month target prices for OraSure Technologies' stock. Their OSUR share price targets range from $5.00 to $9.00. On average, they expect the company's stock price to reach $6.33 in the next twelve months. This suggests that the stock has a possible downside of 9.3%.
View analysts price targets for OSUR
or view top-rated stocks among Wall Street analysts.

How have OSUR shares performed in 2024?

OraSure Technologies' stock was trading at $8.20 at the beginning of 2024. Since then, OSUR stock has decreased by 14.9% and is now trading at $6.98.
View the best growth stocks for 2024 here
.

When is OraSure Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our OSUR earnings forecast
.

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) released its quarterly earnings results on Tuesday, February, 27th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.09. The medical instruments supplier had revenue of $75.88 million for the quarter, compared to analyst estimates of $74.13 million. OraSure Technologies had a trailing twelve-month return on equity of 14.50% and a net margin of 13.23%. The firm's revenue was down 38.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.21 earnings per share.

What ETF holds OraSure Technologies' stock ?

Amplify Treatments, Testing and Advancements ETF holds 20,685 shares of OSUR stock, representing 0.92% of its portfolio.

What guidance has OraSure Technologies issued on next quarter's earnings?

OraSure Technologies issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50.0 million-$54.0 million, compared to the consensus revenue estimate of $57.6 million.

What is Stephen Tang's approval rating as OraSure Technologies' CEO?

2 employees have rated OraSure Technologies Chief Executive Officer Stephen Tang on Glassdoor.com. Stephen Tang has an approval rating of 100% among the company's employees. This puts Stephen Tang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), Energy Transfer (ET), XOMA (XOMA), Overstock.com (OSTK), Ford Motor (F), Pfizer (PFE), Abbott Laboratories (ABT), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.23%), Dimensional Fund Advisors LP (5.32%), Cannell Capital LLC (4.83%), Pacer Advisors Inc. (3.27%), Bridgeway Capital Management LLC (1.08%) and Charles Schwab Investment Management Inc. (1.05%). Insiders that own company stock include Kathleen Gallagher Weber, Michael Celano, Nancy J Gagliano and Ronny B Lancaster.
View institutional ownership trends
.

How do I buy shares of OraSure Technologies?

Shares of OSUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OSUR) was last updated on 3/4/2024 by MarketBeat.com Staff